Oncotarget

Published By:

Impact Journals LLC

Listing Type:

Enhanced

*

p-ISSN:

1949-2553

Founding Year:

2010

Access Model:

Journal Abbreviation:

Oncotarget

Peer Review:

Primary Language:

US English

Impact Factor (

2016

):

5.168

Best Quartile:

Q2

Publication Frequency:

Continuous

APC:

USD

3200

Editor-in-Chief

Wafik S. El-Deiry (Brown University, Providence, RI)



Aims & Scope:

  • Maximize the impact of research via insightful peer-review
  • Link various fields of cancer research, oncology, and biomedical science
  • Foster application of clinical and basic science
  • All pathways, molecules, cell types and functions, and tissues relevant to cancer and related diseases

Article Processing Charges (APC):

  • USD 3,200
  • No fee for invited Research Perspectives, News, and Editorials

Impact Factor (

2016

):

5.168

Best Quartile (

2025

):

Q2

(

Scopus

)

Quartile Details:

  • Q2 in Oncology (Scopus/SCImago; Rank: 141/428)

Journal Citation Index (

):

CiteScore (

2025

):

9

(

Editage

)

h-index

(

2025

):

201

(

Scopus/SJR

)

SJR (

2025

):

0.828

SNIP (

2025

):

1


  • Dimensions (Digital Science)
  • EMBASE
  • MEDLINE
  • META (Chan Zuckerberg Initiative) (2018-2022)
  • PubMed
  • PubMed Central
  • Scopus

Editor-in-Chief

Wafik S. El-Deiry (Brown University, Providence, RI)

Other Members:

Editor-in-Chief

  • Wafik S. El-Deiry (Brown University, Providence, RI)

 

Other Members

  • Ibrahim Abu-Gheida (Burjeel Medical City, Abu Dhabi, UAE)
  • Humaid Obaid Al-Shamsi (Burjeel Cancer Institute, Abu Dhabi, UAE)
  • Trever Bivona (University of California, San Francisco, CA)
  • Phillip Buckhaults (University of South Carolina, Columbia, SC)
  • Fred Bunz (Johns Hopkins University, Baltimore MD)
  • Benedito A. Carneiro (Brown University, Providence, RI)
  • Clark C. Chen (Brown University, Providence, RI)
  • Jonathan Chernoff (Fox Chase Cancer Center, Philadelphia, PA)
  • Stephen G. Chun (University of Texas MD Anderson Cancer Center, Houston, TX)
  • Nathan Dolloff (Medical University of South Carolina (MUSC), Charleston, SC)
  • Peiwen Fei (University of Hawaii Cancer Center, Honolulu, HI)
  • Lori Hazlehurst (West Virginia University and Cancer Institute, Morgantown, WV)
  • Elizabeth P. Henske (Harvard Medical School, Boston, MA)
  • Razelle Kurzrock (Professor of Medicine, Medical College of Wisconsin)
  • Justin D. Lathia (Lerner Research Institute, Cleveland Clinic, Cleveland, OH)
  • Sean Lawler (Brown University, Providence, RI)
  • Bora Lim (University of Texas MD Anderson Cancer Center, Houston, TX)
  • Jia (Jenny) Liu (St Vincent’s Hospital, Sydney, NSW, Australia)
  • Emil Lou (University of Minnesota, Minneapolis, MN)
  • Anirban Maitra (University of Texas MD Anderson Cancer Center, Houston, TX)
  • Ruben A. Mesa (Wake Forest University School of Medicine, Winston Salem, NC)
  • Boris C. Pasche (Barbara Ann Karmanos Cancer Institute, Detroit, MI)
  • Steven A. Rosenzweig (Medical University of South Carolina, Charleston, SC)
  • Yashbir Singh (Mayo Clinic in Rochester, MN)
  • Kumar Somasundaram (Indian Institute of Science, Bangalore, India)
  • Noel Warfel (Dept. of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC)
  • Ashley L. Sumrall (Wake Forest University School of Medicine, Charlotte, NC)
  • Cory Abate-Shen (Columbia University, New York, NY)
  • Dario Altieri (Wistar Institute Cancer Center, Philadelphia, PA)
  • Dafna Bar-Sagi (NYU School of Medicine, New York, NY)
  • Jiri Bartek (Karolinska Institute, Sweden)
  • Stephen Baylin (Johns Hopkins University, Baltimore, MD)
  • Mina J. Bissell (Lawrence Berkeley National Laboratory, Berkeley, CA)
  • Bruce Blazar (University of Minnesota, Minneapolis, MN)
  • Chi Van Dang (Johns Hopkins University, Baltimore, MD)
  • Brian J. Druker (Oregon Health Science University, Portland, OR)
  • Michael A. Dyer (St. Jude Children’s Research Hospital, Memphis, TN)
  • Andrew Feinberg (Johns Hopkins University School of Medicine, Baltimore, MD)
  • Dean W. Felsher (Stanford University School of Medicine, Stanford, CA)
  • Antonio Giordano (Temple University, Philadelphia, PA)
  • Scott E. Kern (Johns Hopkins University, Baltimore, MD)
  • John S. Lazo (UVA Cancer Center, Charlottesville, VA)
  • Arnold Levine (Institute for Advanced Study, Princeton, NJ)
  • Michael P. Lisanti (University of Salford, Salford, UK)
  • Gerry Melino (University of Rome, Rome, Italy)
  • Harold L. Moses (Vanderbilt-Ingram Cancer Center, Nashville, TN)
  • Nickolas Papadopoulos (Johns Hopkins University, Baltimore, MD)
  • Carol Prives (Columbia University, New York, NY)
  • Edward V. Prochownik (University of Pittsburgh School of Medicine)
  • Neal Rosen (Memorial Sloan-Kettering Cancer Center, New York, NY)
  • Alexander Varshavsky (California Institute of Technology, Pasadena, CA)
  • Bert Vogelstein (Johns Hopkins University, Baltimore, MD)
  • Peter K. Vogt (The Scripps Research Institute, La Jolla, CA)

  • Editorials and Commentaries
    • Generally invited
    • Brief discussion of published papers
    • 800 words
    • Less than 7 references

 

  • Research Papers
    • No word limit; no reference limit
    • Abstract: 200 words
    • Section order: Title > Authors > Affiliations > Contact Information > Keywords (5) > Abstract > Introduction > Results > Discussion > Methods or Materials and Methods > Abbreviations > Author Contributions > Acknowledgments > Conflicts of Interest > Ethical Statement > Consent > Funding > References
    • Ethical approval statement and informed consent mandatory for human studies
    • Ethical approval statement mandatory for animal studies
    • No running title required

 

  • Reviews
    • Must have at least 90 references
    • Must have 1–6 tables or figures

 

  • Research Perspectives
    • Topical discussions on recent advancements
    • Might reference unpublished and published material
    • Noo figure count limit
    • Abstract and keywords required
    • At least 70 references

 

  • Meeting Reports
    • Reports from symposia or conferences on cancer research and related fields
    • To be submitted within 3 months of meeting

 

  • Clinical Research Papers and Case Reports
    • Must be conducted in accordance with the guidelines of the Declaration of Helsinki
    • Ethical approval statement and informed consent required

URLs

  • https://oncotarget.msubmit.net/cgi-bin/main.plex?form_type=display_auth_instructions
  • https://www.oncotarget.com/editorial-policies/#format-and-style

 

Miscellaneous

  • Review Process: Single blind
  • Language: US English
  • Acceptable manuscript formats: MS Word (.doc/.docx) or LaTeX (.tex)
  • Ensure the equations, if any, are editable
  • SI units throughout the article
  • Materials and Methods section to be added after the Discussion section
  • Headings on separate lines

 

Title Page

  • Title: Concise and informative. Avoid formulae and abbreviations.
  • Author names and affiliations
  • Corresponding author details
  • 5 keywords
  • Total number of figures and tables

 

Abstract

  • Unstructured
  • Word-limit: 200 words
  • Avoid references

 

Figures

  • Submit each figure as a separate file, named as Figure 1, Figure 2, etc.
  • For multi-panel figures, the images originally used to generate each panel must be submitted additionally
  • Resolution must be higher than 300 dpi
  • Number and cite the figures sequentially
  • Accepted file formats: TIFF, PNG, and EPS
  • Legends submitted in the main manuscript file; define all abbreviations used in a figure and its legend at the end of the corresponding legend

 

Tables

  • Editable text and not images
  • Number and cite sequentially
  • Placed in the main manuscript file in a separate section at the end of the manuscript
  • Avoid using tabs and spaces to build the structure of the table

 

Citations

  • Numbered citations in square brackets

 

References

  • Up to 13 authors are to be listed in a reference; “et al.” to be used only after that
  • Format for all papers except editorials:
    • Journal article: <first author lastname><firstname initials>, <second author lastname><firstname initials>. Article title. Journal. Year of publication; Volume no.: Page range.
    • Book article: Any format is acceptable
    • Article in press: Acceptable only if journal name and publication year (tentative) is available
  • Format for all editorials:
    • <first author lastname>, et al. Journal. Year of publication; Volume no.: Page range.
    • No article titles

 

Supplementary Files

  • Preferred file formats:
    • TIFF, PNG, and EPS for figures
    • Word and Excel for tables
  • Cite all material in the manuscript
  • Tables in Excel are accepted but not recommended

 

Funding Sources

  • Add funding details, including the sources and numbers of grants

 

Conflict of Interests

  • All studies must have this statement, whether there are any conflicts or not

 

Acknowledgments

  • List individuals who helped with the research
  • The corresponding author should get permission from the individuals to be listed in this section

 

Author Contributions

  • Include contributions in the final article

Template File


To be Updated


Listing Type:

Enhanced

This journal’s profile is presented under the Enhanced listing level. Listing levels determine the information and resources included in a profile. They are not ratings, rankings, certifications, endorsements, or assessments of journal quality or credibility.